Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PhoreMost","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"PhoreMost","sponsor":"Vipergen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vipergen Establishes Research Partnership with Phore Most Focused on Dna Encoded Library (DEL)-Based Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"PhoreMost","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PhoreMost Enters Multi-Project Drug Target Discovery Collaboration with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by PhoreMost

    Menu

    PhoreMost

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PhoreMost

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PhoreMost Enters Multi-Project Drug Target Discovery Collaboration with Roche

              Details:

              Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PhoreMost

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vipergen Establishes Research Partnership with Phore Most Focused on Dna Encoded Library (DEL)-Based Drug Discovery

              Details:

              Under the terms of the agreement Vipergen will apply its leading technologies for DNA-encoded library synthesis and screening including DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Recipient: Vipergen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PhoreMost

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies

              Details:

              PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.

              Lead Product(s): LentiVector based gene therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Oxford Biomedica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY